Tag: CTAD 2025
-
Lighthouse Pharmaceuticals to Present Phase 2 SPRING Trial of LHP588 at CTAD 2025
Overview of the SPRING Trial and LHP588 Lighthouse Pharmaceuticals, a Novato, California-based clinical-stage biopharmaceutical company, is poised to share new data from its Phase 2 SPRING trial of LHP588, a next-generation gingipain inhibitor designed to address P. gingivalis-positive Alzheimer’s disease. Gingipains are enzymes produced by the oral bacterium Porphyromonas gingivalis, which researchers have linked to…
-
Lighthouse Pharmaceuticals to Present Phase 2 SPRING Trial of LHP588 for P. gingivalis–Positive Alzheimer’s at CTAD 2025
Overview: A Targeted Approach to a Complex Neurodegenerative Challenge In a bid to address an emerging and controversial hypothesis in Alzheimer’s disease (AD) research, Lighthouse Pharmaceuticals announced the Phase 2 SPRING trial results for LHP588, a next-generation gingipain inhibitor, at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference. The company positions LHP588 as a…